Testing a Community Intervention to Increase Aspirin Use
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02607917|
Recruitment Status : Recruiting
First Posted : November 18, 2015
Last Update Posted : November 15, 2018
|Condition or disease||Intervention/treatment||Phase|
|Myocardial Infarction Stroke||Other: Mass Media plus clinic intervention. Other: Media||Not Applicable|
Proposed is a demonstration and implementation project to increase the appropriate use of aspirin for primary prevention of acute myocardial infarction and stroke in the population of Minnesota. Although significant progress in the reduction of acute myocardial infarction and stroke is apparent, these cardiovascular disorders continue as the leading causes of morbidity and mortality. In recent years, and in the context of the positive results from large randomized clinical trials, there is growing consensus that aspirin, when appropriately used, reduces cardiovascular morbidity in men aged 45-79 and women aged 55-79 years. The use of aspirin for primary prevention was recommended in the U.S. Preventive Services Task Force Report in 2009 and more recently in the CDC/CMS 'Million Hearts' ABCs (aspirin, blood pressure, cholesterol, smoking) campaign. Aspirin use is also recommended in the Healthy People 2020 goals. However, many adults who would benefit, are not taking aspirin.
The investigators have been fortunate to receive a large philanthropic donation to launch a campaign to increase appropriate aspirin use in the State of Minnesota. The proposed grant requests funding to evaluate that campaign and the innovative approaches it proposes. In the context of a innovative mass media effort, the investigators intend to test new methods for health system change to increase appropriate aspirin use. Using a two-arm design, the investigators have defined 24 geographic areas in the state that will form the basis for a group-randomized trial. This design will allow us to distinguish the effects of the intervention methods. The interventions will be evaluated by sequential surveys of the target-age general population at baseline and follow-up. Appropriate aspirin use in that population will be the primary goal and endpoint. Simultaneous surveys of adjacent Upper Midwestern states (Iowa, North and South Dakota, Wisconsin) will assess secular trends. Morbidity and mortality data will monitor disease trends and complications associated with aspirin use.
A substantial pilot study in a middle sized community in Northern Minnesota allows us to refine and validate our intervention and measurement methods at the community level. This pilot also demonstrated behavior change of a magnitude supportive of our design assumptions.
This program, if successful, should result in a generalizable program tested in a real world population setting.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10800 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Testing a Community Intervention to Increase Aspirin Use for Primary Prevention of Cardiovascular Disease|
|Study Start Date :||December 2014|
|Estimated Primary Completion Date :||July 2019|
|Estimated Study Completion Date :||November 2019|
Experimental: Mass Media plus clinic intervention.
These geographic areas will receive the media plus clinic intervention over a two year period.
Other: Mass Media plus clinic intervention.
These geographic areas will receive the media intervention over a two year period.
No Intervention: No Intervention
Adjacent states will receive no intervention.
- Appropriate aspirin use. [ Time Frame: 4-5 years ]Aspirin use will be determined by standardized surveys of randomly selected adults.
- Cardiovascular disease morbidity [ Time Frame: 4-5 years ]Collected from hospital records of the Minnesota Hospital Association.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02607917
|Contact: Russell V Luepker, MD, MSemail@example.com|
|Contact: Alan T Hirsch, MDfirstname.lastname@example.org|
|United States, Minnesota|
|University of Minnesota||Recruiting|
|Minneapolis, Minnesota, United States, 55455|
|Contact: Russell Luepker 612-624-6362 email@example.com|